CARMAT boosts its sales and affirms its development

CARMAT, designer of the Aeson® artificial heart, announced a significant increase in its implantations for the first half of 2024. The company carried out 20 implantations during the first six months of the year, generating a turnover of 3.2 M€, exceeding the annual total for 2023.

Stéphane Piat, Managing Director of CARMAT, is delighted with the positive results and the rapid adoption of Aeson® by healthcare professionals. The momentum of the EFICAS study in France is notable, with 14 implementations carried out at the start of the year. The results of this study are planned for the end of 2025.

CARMAT's commercial network is expanding, with 42 trained hospitals and sales in three active countries: Germany, Italy and Poland. The company plans to activate more countries in the second half of 2024.

Aeson®'s awareness continues to grow within the medical community, supported by positive feedback and increased presence at scientific conferences.